Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Bird & Bird, Foley Hoag LLP, Goodwin Procter, advised on the matter. Bird & Bird advised SparingVision SAS with a team including Emmanuelle Porte...
You must be a Standard 1 Year member to access this content.
Hogan Lovells represented Intellia Therapeutics on the matter. Intellia Therapeutics launched a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company in a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Intellia Therapeutics on the deal. Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever...
You must be a Standard 1 Year member to access this content.
